Senators delay start for possible PBM reforms; biotechs look beyond Wegovy and Ozempic with novel strategies

Taking stock of the drug industry, from the lab to the medicine chest

May 1, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Chip Somodevilla/Getty Images STAT+ | Senators delay start date for possible PBM reforms Senators drafting reforms to PBMs have delayed their effective date by at least 10 months, according to documents obtained by STAT. By Rachel Cohrs and John Wilkerson STAT+ | Beyond Wegovy and Ozempic: Biotechs vie for piece of red-hot weight loss market with novel strategies Emerging from an investment desert, startups hope their weight loss drugs will have a unique edge, like protecting muscle. By Elaine Chen and Allison DeAngelis STAT+ | Sam Waksal and Jeremy Levin plot 'the turnaround story of the century' Sam Waksal, the storied drug developer, and his longtime friend Jeremy Levin, the CEO of Ovid, plot "the turnaround story of the century." By Damian Garde Adobe STAT+ | Astellas acquires Iveric Bio for $5.9B, entering competition to treat common cause of vision loss The Japanese drugmaker is betting on a prospective treatment for a form of vision loss that affects around 1 million people in the U.S. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser